Janssen-Cilag's Stelara approved in EU for psoriasis
This article was originally published in Scrip
The European Commission has approved Janssen-Cilag's (Johnson & Johnson) novel human monoclonal antibody drug Stelara (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis in adults who have failed to respond to, are intolerant to, or have a contraindication to other systemic therapies including ciclosporin, methotrexate and psoralen plus ultraviolet light (PUVA).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.